We are live on ! Find out more
EBS icon

Emergent Biosolutions
EBS

238 hedge funds and large institutions have $1.88B invested in Emergent Biosolutions in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

373% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 11

73% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 60

25% more capital invested

Capital invested by funds: $1.5B → $1.88B (+$378M)

20% more funds holding

Funds holding: 198 → 238 (+40)

7.58% more ownership

Funds ownership: 90% → 97.58% (+7.6%)

47% less call options, than puts

Call options by funds: $684K | Put options by funds: $1.29M

Holders
238
Holders Change
+40
Holders Change %
+20.2%
% of All Funds
5.4%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
52
Increased
104
Reduced
60
Closed
11
Calls
$684K
Puts
$1.29M
Net Calls
-$609K
Net Calls Change
-$1.63M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$24.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$18.2M
3
AAMU
Amundi Asset Management US
Massachusetts
+$14.9M
4
O
OppenheimerFunds
New York
+$13.6M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$11.1M

Top Sellers

Rank Fund Capital Flow
1
GT
Glenmede Trust
Pennsylvania
-$22.3M
2
Fidelity International
Fidelity International
Bermuda
-$11.2M
3
Charles Schwab
Charles Schwab
California
-$6.03M
4
GAM
Gotham Asset Management
New York
-$4.93M
5
Bank of America
Bank of America
North Carolina
-$4.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
SWM
226
SeaCrest Wealth Management
New York
$5K +$4.59K +109 New
GAM
227
Gemmer Asset Management
California
$4K – – –
SPIA
228
Steward Partners Investment Advisory
New York
$4K – – –
WAM
229
Wealthspire Advisors (Maryland)
Maryland
$4K +$3.16K +75 +2,500%
SEI Investments
230
SEI Investments
Pennsylvania
$3K +$926 +22 +54%
BTIS
231
BB&T Investment Services
North Carolina
$2K – – –
TWA
232
TCI Wealth Advisors
Arizona
$2K – – –
Northwestern Mutual Wealth Management
233
Northwestern Mutual Wealth Management
Wisconsin
$2K +$2.02K +48 New
IA
234
IFP Advisors
Florida
$1K – – –
PFBT
235
Parkside Financial Bank & Trust
Missouri
$1K – – –
ST
236
Smithfield Trust
Pennsylvania
$1K +$842 +20 New
PCG
237
Private Capital Group
Connecticut
$1 +$3.12K +74 New
IA
238
Icon Advisers
Colorado
– -$1.68M -41,500 Closed
NFA
239
Nationwide Fund Advisors
Ohio
– -$1.05M -25,881 Closed
Bank of Nova Scotia
240
Bank of Nova Scotia
Ontario, Canada
– -$291K -7,200 Closed
JG
241
Jefferies Group
New York
– -$212K -5,243 Closed
BCM
242
BTC Capital Management
Iowa
– -$208K -5,155 Closed
N
243
Natixis
France
– -$203K -5,018 Closed
SG Americas Securities
244
SG Americas Securities
New York
– -$202K -4,999 Closed
PCM
245
Prelude Capital Management
New York
– -$69K -1,700 Closed
TRCT
246
Tower Research Capital (TRC)
New York
– -$58K -1,433 Closed
QT
247
Quantbot Technologies
New York
– -$27K -679 Closed
KF
248
Krilogy Financial
Missouri
– -$8K -200 Closed
VCM
249
Virtue Capital Management
Tennessee
– +$84 +2 New
6 7 8 9
10

EBS Hedge Fund Activity: Q4 2017 in Review

238 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2017, worth a combined $1.88B — up 25% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new EBS positions and 11 closed out — a net gain of 41 holders — while 104 added to existing stakes and 60 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $24.3M. The largest seller was Glenmede Trust, cutting an estimated $22.3M.

  • 238 institutional investors held Emergent Biosolutions (EBS) as of Q4 2017, up from 198 in Q3 2017.
  • Funds reported $1.88B of Emergent Biosolutions stock for Q4 2017, up 25% quarter-over-quarter.
  • 52 funds opened new Emergent Biosolutions positions in Q4 2017 and 11 closed out, a net change of +41 holders.
  • The largest Emergent Biosolutions buyer in Q4 2017 was Goldman Sachs, an estimated $24.3M added.
  • The largest Emergent Biosolutions seller in Q4 2017 was Glenmede Trust, an estimated $22.3M sold.

Based on aggregated 13F filings for Q4 2017.